Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

PR Newswire (AI)October 28, 2026en

PR Newswire (AI)

AI Global Wire

Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients REHOVOT, Israel, Oct. 28, 2026 ...

This is a short summary published by AI Global Wire. The full article is owned and hosted by PR Newswire (AI) — open it there to read it in full.